Y. Matsumoto et al., Pharmacokinetics and pharmacodynamics of serum platinum of gynecologic cancer patients treated with nedaplatin, ONCOL REP, 8(6), 2001, pp. 1269-1273
Nedaplatin (cis-diammine glycolate platinum) is one of the effective platin
um agents for gynecologic carcinoma. In order to assess the pharmacokinetic
s and pharmacodynamics of serum platinum of gynecologic cancer patients tre
ated with nedaplatin, we calculated 10 course AUCs (area under the curve) o
f the free and total platinum from blood samples of 4 patients. Peak serum
platinum concentrations were dependent on infusion times. In the case of a
patient with renal dysfunction or ascites, the concentration of serum plati
num tended to stay at a high level for a long time. Serum-free platinum rat
ios were maintained longer than cisplatin. Low dose nedaplatin administrati
on and divided administration were effective, but total AUC was not so grea
t. The relation between AUC ratio (free platinum AUC/ total platinum AUC) a
nd dose/m(2) was not clarified.